Immunotherapies for pediatric cancer: current landscape and future perspectives
-
Published:2019-12
Issue:4
Volume:38
Page:573-594
-
ISSN:0167-7659
-
Container-title:Cancer and Metastasis Reviews
-
language:en
-
Short-container-title:Cancer Metastasis Rev
Author:
Hutzen Brian,Paudel Siddhi Nath,Naeimi Kararoudi Meisam,Cassady Kevin A.,Lee Dean A.,Cripe Timothy P.
Abstract
AbstractThe advent of immunotherapy has revolutionized how we manage and treat cancer. While the majority of immunotherapy-related studies performed to date have focused on adult malignancies, a handful of these therapies have also recently found success within the pediatric space. In this review, we examine the immunotherapeutic agents that have achieved the approval of the US Food and Drug Administration for treating childhood cancers, highlighting their development, mechanisms of action, and the lessons learned from the seminal clinical trials that ultimately led to their approval. We also shine a spotlight on several emerging immunotherapeutic modalities that we believe are poised to have a positive impact on the treatment of pediatric malignancies in the near future.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference192 articles.
1. Huehls, A. M., Coupet, T. A., & Sentman, C. L. (2015). Bispecific T-cell engagers for cancer immunotherapy. Immunology and Cell Biology, 93(3), 290–296. 2. Brischwein, K., Parr, L., Pflanz, S., Volkland, J., Lumsden, J., Klinger, M., Locher, M., Hammond, S. A., Kiener, P., Kufer, P., Schlereth, B., & Baeuerle, P. A. (2007). Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. Journal of Immunotherapy, 30(8), 798–807. 3. Scheuermann, R. H., & Racila, E. (1995). CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leukemia & Lymphoma, 18(5–6), 385–397. 4. Loffler, A., et al. (2000). A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood, 95(6), 2098–2103. 5. Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., Einsele, H., Brandl, C., Wolf, A., Kirchinger, P., Klappers, P., Schmidt, M., Riethmüller, G., Reinhardt, C., Baeuerle, P. A., & Kufer, P. (2008). Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science, 321(5891), 974–977.
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|